- The European Medicines Agency's advisory group CHMP adopts a positive opinion backing approval for Merck's (NYSE:MRK) DELSTRIGO (doravirine, lamivudine and tenofovir disoproxil fumarate) and PIFELTRO (doravirine) for the treatment of adults with chronic HIV-1 infection.
- A final decision by the European Commission usually takes ~60 days.
European advisory group backs Merck's HIV meds Delstrigo and Pifeltro
Recommended For You
About MRK Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MRK | - | - |
Merck & Co., Inc. |